HPGC Renmintongtai Pharmaceutical Corporation (SHA:600829)
China · Delayed Price · Currency is CNY 10.27
-0.44 (-4.11%)
Aug 20, 2026, 3:00 PM CST
SHA:600829 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 5,955 | 6,269 | 4,349 | 4,535 | 3,700 | 3,897 | |
Market Cap Growth | 23.73% | 44.13% | -4.09% | 22.57% | -5.06% | -9.43% |
Enterprise Value | 5,963 | 6,382 | 4,499 | 4,654 | 3,912 | 4,575 |
Last Close Price | 10.27 | 10.81 | 7.50 | 7.62 | 6.22 | 6.55 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 41.87 | 46.84 | 20.39 | 15.52 | 13.99 | 14.05 |
Forward PE | - | 23.62 | 23.62 | 23.62 | 23.62 | 23.62 |
PS Ratio | 0.56 | 0.60 | 0.43 | 0.44 | 0.38 | 0.42 |
PB Ratio | 1.92 | 2.08 | 1.51 | 1.65 | 1.51 | 1.77 |
P/TBV Ratio | 1.94 | 2.10 | 1.52 | 1.66 | 1.52 | 1.80 |
P/FCF Ratio | - | 22.17 | 40.50 | 14.65 | 12.30 | - |
P/OCF Ratio | 677.93 | 20.90 | 37.68 | 13.62 | 12.04 | - |
PEG Ratio | - | 0.76 | 0.76 | 0.76 | 0.76 | 0.76 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.56 | 0.62 | 0.45 | 0.45 | 0.41 | 0.49 |
EV/EBITDA Ratio | 19.97 | 26.31 | 14.05 | 10.78 | 9.69 | 10.48 |
EV/EBIT Ratio | 24.75 | 28.27 | 15.00 | 11.31 | 10.21 | 11.08 |
EV/FCF Ratio | - | 22.57 | 41.89 | 15.04 | 13.00 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.25 | 0.24 | 0.31 | 0.37 | 0.52 | 0.60 |
Debt / EBITDA Ratio | 2.58 | 2.59 | 2.49 | 2.16 | 2.84 | 2.80 |
Debt / FCF Ratio | - | 2.59 | 8.38 | 3.29 | 4.22 | - |
Net Debt / Equity Ratio | 0.00 | -0.17 | -0.07 | -0.11 | 0.04 | 0.24 |
Net Debt / EBITDA Ratio | 0.03 | -2.07 | -0.62 | -0.68 | 0.22 | 1.21 |
Net Debt / FCF Ratio | -0.41 | -1.78 | -1.86 | -0.95 | 0.29 | -2.15 |
Asset Turnover | 1.51 | 1.45 | 1.38 | 1.44 | 1.40 | 1.46 |
Inventory Turnover | 8.54 | 8.18 | 8.29 | 8.59 | 8.02 | 7.48 |
Quick Ratio | 1.38 | 1.34 | 1.33 | 1.27 | 1.22 | 1.15 |
Current Ratio | 1.71 | 1.67 | 1.62 | 1.53 | 1.48 | 1.42 |
Return on Equity (ROE) | 4.70% | 4.54% | 7.57% | 11.22% | 11.36% | 13.19% |
Return on Assets (ROA) | 2.13% | 1.97% | 2.57% | 3.55% | 3.47% | 4.05% |
Return on Invested Capital (ROIC) | 5.62% | 6.14% | 8.61% | 12.23% | 11.12% | 12.97% |
Return on Capital Employed (ROCE) | 7.40% | 7.10% | 9.90% | 14.20% | 14.60% | 17.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.39% | 2.14% | 4.90% | 6.44% | 7.15% | 7.12% |
FCF Yield | -0.32% | 4.51% | 2.47% | 6.83% | 8.13% | -6.29% |
Dividend Yield | - | - | - | 1.89% | - | - |
Payout Ratio | 13.18% | 15.00% | 75.22% | 8.43% | 11.53% | 12.86% |
Buyback Yield / Dilution | -0.04% | -0.01% | 0.01% | -0.01% | 0.00% | 0.20% |
Total Shareholder Return | -0.04% | -0.01% | 0.01% | 1.88% | 0.00% | 0.20% |